A J Ten Tije
Overview
Explore the profile of A J Ten Tije including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mulder E, de Joode K, Litiere S, Ten Tije A, Suijkerbuijk K, Boers-Sonderen M, et al.
BMC Cancer
. 2021 Mar;
21(1):323.
PMID: 33765967
Background: The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration...
2.
Bouwer N, Steenbruggen T, van Rosmalen J, Rier H, Kitzen J, van Bekkum M, et al.
Breast Cancer Res Treat
. 2021 Jan;
186(3):851-862.
PMID: 33394273
Purpose: Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF) monitoring. We...
3.
van Zeijl M, de Wreede L, van den Eertwegh A, Wouters M, Jochems A, Schouwenburg M, et al.
Eur J Cancer
. 2020 Dec;
144:242-251.
PMID: 33373869
Background: The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time in daily clinical practice. Methods: From a...
4.
Boekhout A, Rogiers A, Jozwiak K, Boers-Sonderen M, van den Eertwegh A, Hospers G, et al.
Acta Oncol
. 2020 Sep;
60(1):69-77.
PMID: 32924708
Background: Checkpoint inhibitors have changed overall survival for patients with advanced melanoma. However, there is a lack of data on health-related quality of life (HRQoL) of long-term advanced melanoma survivors,...
5.
Mackay T, Smits F, Latenstein A, Bogte A, Bonsing B, Bos H, et al.
Trials
. 2020 Apr;
21(1):334.
PMID: 32299515
Background: Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical...
6.
van der Werf A, Langius J, Beeker A, Ten Tije A, Vulink A, Haringhuizen A, et al.
Clin Nutr
. 2020 Feb;
39(10):3005-3013.
PMID: 32037284
Background & Aims: A low muscle mass before start of treatment and loss of muscle mass during chemotherapy is related to adverse outcomes in patients with cancer. In this randomized...
7.
Steenbruggen T, Bouwer N, Smorenburg C, Rier H, Jager A, Beelen K, et al.
Breast Cancer Res Treat
. 2019 Sep;
178(3):597-605.
PMID: 31493033
Purpose: Patients with HER2-positive metastatic breast cancer (MBC) treated with trastuzumab may experience durable tumor response for many years. It is unknown if patients with durable radiological complete remission (rCR)...
8.
Corrie P, Terheyden P, Ten Tije A, Herbst R, Jansen R, Marples M, et al.
Br J Dermatol
. 2018 Nov;
180(5):1254-1255.
PMID: 30488430
No abstract available.
9.
Dierks J, Gaspersz M, Belkouz A, van Vugt J, Coelen R, de Groot J, et al.
Acta Oncol
. 2017 Dec;
57(6):807-812.
PMID: 29265948
Background: Biliary tract cancer (BTC) is an uncommon cancer with an unfavorable prognosis. Since 2010, the standard of care for patients with unresectable BTC is palliative treatment with gemcitabine plus...
10.
Verstijnen J, Damude S, Hoekstra H, Kruijff S, Ten Tije A, Louwman W, et al.
Surg Oncol
. 2017 Nov;
26(4):431-437.
PMID: 29113662
Background: Due to the lack of solid evidence for treatment benefit of Sentinel Lymph Node Biopsy (SLNB) as part of loco-regional surgical treatment of non-distant metastatic melanoma, there might be...